Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or refractory multiple myeloma, including those in difficult-to-treat subgroups, in a multi-center, international study reported to the 2024 American Association for Cancer Research Annual Meeting.

After giving his talk in San Diego, lead author Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology and Director of the Center of Excellence for Multiple Myeloma at the Icahn School of Medicine at Mount Sinai in New York, met up with OncTimesTalk correspondent Peter Goodwin to discuss the therapeutic progress the drug offers.